Follow us on Twitter
Below you will find current and archived press releases for your associated company. Navigate by selecting the year in the list below and click on the press release you want to read. Distribution takes place with a maximum of five minutes delay from press release.
As we had expected, Nanexa announced a SEK 121m rights issue, albeit at a slightly higher than expected both discount and amount. Th...
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONGKONG, ...
Nanexa AB today announced that its scientific abstract has been accepted for the international health economic conference ISPOR Euro...
Nanexa AB (publ) today announced that the company has been granted a patent in India relating to its PharmaShell® technology. This p...
Nanexa’s Q2’23 advancements with NEX-20 and NEX-22 underscore the company’s forward momentum. NEX-20 is set to provide a more detail...
Strong preclinical progress with NEX-22, positive Phase 1 data with NEX-20 and several partner projects in preclinical evaluation
...
Nanexa AB (publ) will publish its report for the second quarter of 2023 tomorrow August 23, 2023 and invites to a comment of the rep...
Nanexa AB today announced that a preclinical study of NEX-22 in minipigs confirms a long release profile of liraglutide, which was p...
Nanexa AB today announced that pharmacokinetic data from the Phase 1 study NEX-20-01 confirmed a release profile of lenalidomide in ...
The second quarter of 2023 has come to its end and many of us in Sweden go into the holiday season. We at Nanexa can summarize the f...
The Annual General Meeting (AGM) of Nanexa AB (publ) has been held on June 9, 2023, at which meeting submitted proposals were passed...
Nanexa AB today announced that the recruitment and dosing has been completed in the NEX-20 Phase 1 study. Since December last year, ...
Nanexa AB today announced that the company is engaging the contract research organization (CRO) Profil, in Neuss, Germany, ahead of ...
The shareholders in Nanexa AB (publ) reg. no. 556833–0285 (the “Company”) are hereby given notice that the annual general meeting wi...
After positive pre-clinical results in rats with NEX-22 (for treatment of type 2 diabetes) in Q1, we now see results from phase I fo...
Positive pre-clinical data with NEX-22, NEX-20 phase I continues and good progress in partner projects
Significan...
Nanexa AB (publ) today announced that the annual report for 2022 has been published and is available on the company's website
...
Nanexa AB (publ) today announced positive outcome in the first preclinical study with NEX-22. In a one-month study in rats, single d...
90 Second Pitch with drug delivery company NANEXA (Nasdaq First North) that recently signed a deal with NOVO NORDISK triggering a +100% surg...
After a news packed Q4 2022, including an exclusivity and evaluation agreement with Novo Nordisk, start of Phase I with NEX-20 and t...
Agreement and directed issue to Novo Nordisk, solution to patent infringement lawsuit and phase 1 study with NEX-20 started
...
Nanexa AB (publ) will tomorrow, the 16th of February, 2023, publish its year-end report for the fiscal year 2022 and interim report ...
On February 7-8, Nanexa participates in Lugano, Switzerland, as one of the sponsors at the 4th annual ”Beyond Medicines’ Barriers Me...
